Open access
Aug 2026
MDM2 inhibition restores p53 function to overcome dual endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer
The case for clinical evaluation of MDM2 inhibition in this setting of urgent clinical need is supported, as NVP-CGM097 demonstrates single agent efficacy in dual-resistant ER+ breast cancer through G 1 arrest and senescence.
Leila Eshraghi, Fiona H. Zhou, Sarah Alexandrou et al.
· Breast Cancer Research · 0 citations